17results about How to "Small systemic side effects" patented technology

The invention discloses construction and application of an oral gel drug delivery system based on a yeast microcapsule, and belongs to the field of new auxiliary materials and new dosage forms of pharmaceutical preparations, the drug delivery system is composed of budesonide nanoparticles, the yeast microcapsule and gel, budesonide nanoparticles are prepared from budesonide and a polylactic acid-glycolic acid copolymer through a water-in-oil emulsification evaporation technology, yeast cell wall microcapsules are formed after content of yeast powder is removed, and the budesonide-loaded yeast microcapsules are prepared from the yeast microcapsules and the budesonide nanoparticles through stirring, ultrasonic treatment and freeze drying methods. The yeast cell wall microcapsule without contents is used as a carrier, so that the medicine is protected from being degraded by gastric acid, and the intestinal immune response is regulated by targeting intestinal related lymphatic tissues (GALT). The gel prepared by combining pectin can prolong the residence time of the drug in the intestinal tract, realizes continuous release, reduces the whole-body side effect of budesonide, and improves the treatment efficiency.

The invention relates to the technical field of medical instruments, in particular to a photo-initiation medicine balloon catheter which comprises a catheter body, a balloon fixedly arranged at the far end of the catheter body, a catheter base fixedly arranged at the near end of the catheter body and a plurality of micro spraying pipes fixedly arranged on the outer surface of the balloon. Wherein the catheter main body comprises a first catheter, and a second catheter which is fixedly arranged outside the first catheter in a sleeving manner; wherein a first pipe cavity is formed between the inner wall of the second guide pipe and the outer wall of the first guide pipe, and a plurality of second pipe cavities are arranged between the outer wall of the second guide pipe and the inner wall of the second guide pipe in an annular array mode with the axis of the second guide pipe as the reference; through local administration, the photosensitizer is efficiently activated, the side effects of the whole body are reduced, the treatment effect on diseases such as bile duct cancer is improved, the medical cost is reduced, and the living quality of a patient is also improved.

The invention relates to the technical field of nano biological medicines, and discloses a photo-thermal-enzyme catalysis nano-particle as well as a preparation method and application thereof. The photo-thermal-enzyme catalysis nano-particles are constructed by crosslinking water-soluble self-doped polyaniline nano-particles, human serum albumin, lactate oxidase and collagenase through a thioacetal linker capable of being split by active oxygen. Collagenase and lactate oxidase (LOx) are integrated into the same nanoparticle system through a thioacetal (TK) linker, the TK linker is split under the action of tumor microenvironment active oxygen (ROS) and H2O2 generated by catalysis of the LOx, the activity of the two enzymes is synchronously activated, a collagen matrix (physical barrier) is degraded, lactic acid (chemical barrier) is removed, the tumor microenvironment is efficiently remodeled, and the tumor microenvironment can be effectively inhibited. The problems that the regulation effect of a single barrier is limited, and the tumor microenvironment is difficult to improve are solved.

The invention provides preparation and application of a PKM2 enzyme response polypeptide hydrogel capable of simultaneously delivering PTX and GDC0919. The first purpose of the invention is to provide a polypeptide molecule Nap-T, and the Nap-T is a Nap-FFF fragment and an amino acid fragment as shown in SEQ ID NO.1 which are sequentially connected from an N terminal to a C terminal. The invention also provides a PKM2 enzyme response polypeptide hydrogel capable of simultaneously delivering PTX and GDC0919. The PKM2 enzyme response polypeptide hydrogel comprises the polypeptide molecule Nap-T, a chemotherapeutic drug and an IDO inhibitor. The polypeptide molecule Nap-T is self-assembled into hydrogel and wraps a chemotherapeutic drug and an IDO inhibitor. On the basis that PTX and GDC0919 are wrapped by the polypeptide hydrogel, the curative effect of PTX in NSCLC treatment can be improved, and the IDO-mediated immunosuppression effect is overcome. Based on a peptide sequence of a PKM2 phosphorylation substrate on the polypeptide molecule Nap-T, the hydrogel has PKM2 enzyme responsiveness and is gradually degraded under high-level PKM2 enzyme activity in tumor tissues, accurate and continuous release of drugs is achieved, and the treatment experience and life quality of patients are improved.

The present invention relates to a cytohormone fusion protein comprising a cytohormone domain that can specifically induce an immune cell targeting domain and proliferation and / or activation of immune cells. Specifically, the present invention relates to a fusion protein that specifically delivers a cytohormone (e.g., IL-2 or IL-15) to a depleted immune cell (e.g., a depleted T cell) within a tumor, thereby inducing and enhancing the activation of the immune cell. The fusion protein according to the present invention can selectively deliver a cytohormone that promotes the proliferation or activation of immune cells to effector T cells or the like in a tumor microenvironment, thereby inducing a strong immune enhancement and anti-cancer response in a tumor. Moreover, through the unique structure of the cytohormone action domain, systemic toxicity and even side effects caused by the cytohormone can be obviously reduced.

The present application provides an intervertebral fusion cage, which comprises an upper support plate, a lower support plate arranged in a height direction and below the upper support plate, and a drug releasing part connected between the upper support plate and the lower support plate, wherein the drug releasing part comprises a drug storage part, and when the upper support plate and the lower support plate are pressed, the drug in the drug storage part is squeezed out. The intervertebral fusion cage of the present application realizes micro-targeted drug delivery triggered by activity, precise inhibition of local inflammation and significant reduction of systemic side effects by arranging the drug releasing part comprising the drug storage part.

The invention relates to a plasmid-loaded targeted liposome compound, and a preparation method and application thereof. The liposome compound comprises liposome and plasmid pPEA entrapped by the liposome, and the plasmid pPEA comprises an expression vector pGAVPO containing a blue light induced transcription factor GAVPO protein and pU5-PEA of a light-operated gene expression system capable of expressing PEA. The targeting biological material for modifying the liposome is fused on the liposome to form a liposome compound pPEA (at) GPH-L entrapping the pseudomonas aeruginosa exotoxin light-operated gene and the liposome targeting material. The liposome disclosed by the invention can target tumor cells, has great lethality on the tumor cells, is safe and effective, and has important significance in preparation of anti-tumor medicines, especially medicines for treating breast cancer.

The application provides a low-pressure drug-loaded balloon catheter system for preoperative treatment of abdominal aortic aneurysm endovascular repair and a pre-treatment method, which comprises a catheter main body, a segmented balloon structure is arranged at the distal end of the catheter main body, a drug-loaded coating structure for realizing biological remodeling of the abdominal aortic aneurysm lesion vessel wall is arranged on the outer surface of the segmented balloon structure, the drug-loaded coating structure releases active drugs for inhibiting the pathological progression of abdominal aortic aneurysm under the action of blood flow, a pressure control system in communication with the segmented balloon structure is arranged on the catheter main body, and the pressure control system is used for low-pressure inflation of the segmented balloon structure and adjustment of injection pressure and flow rate. The application improves the local drug delivery efficiency under the premise of ensuring operation safety through the synergistic design of structural design and drug delivery mechanism, and provides a new preoperative intervention strategy for the treatment of abdominal aortic aneurysm.

The invention discloses a fusion polypeptide RAT-1 and application thereof in hypertension treatment. The topological structure of the fusion polypeptide is a kidney targeting head-ACE2 functional segment-MMP responsive connexon-AT1 receptor antagonism segment, and the full-length sequence is as shown in SEQ ID No: 1. The kidney targeting head can be specifically combined with megalin receptors of renal tubular epithelial cells to realize kidney targeting delivery; the ACE2 functional segment can efficiently degrade angiotensin II; the MMP responsive connexon is specifically cut in a focus microenvironment, and an AT1 receptor antagonism segment is released; the AT1 receptor antagonist segment can block the receptor signal channel of angiotensin II. The fusion polypeptide has good plasma stability, shows a powerful and long-acting antihypertensive effect in a spontaneous hypertension rat model, is remarkable in kidney targeting, and can relieve renal fibrosis and protect podocyte functions. The fusion polypeptide disclosed by the invention realizes a synergistic effect of targeted delivery, enzymolysis catalysis, response release and receptor antagonism, and can be used for preparing hypertension treatment medicines and kidney protection medicines.

The invention discloses multifunctional injectable composite hydrogel loaded with active oxygen response polymeric micelles and a preparation method and application of the multifunctional injectable composite hydrogel, and belongs to the technical field of biomedical hydrogels, oxidized hyaluronic acid, modified chitosan and active oxygen sensitive micelles are fused in the hydrogel, and intelligent regulation and control over the rheumatoid arthritis microenvironment are achieved. Through a dual crosslinking technology, the hydrogel not only has improved mechanical strength, but also has shape adaptation and self-repairing capabilities. Due to introduction of the active oxygen response micelle, drug release is intelligent, the release rate is adjusted according to the level of active oxygen in joints, and the curative effect is enhanced; the hydrogel can accurately locate an inflamed joint, intelligently release drugs, reduce side effects, induce polarization of M2 macrophages, improve an inflammatory microenvironment and realize collaborative treatment, intelligent controlled release and long-term stability of the hydrogel provide a new strategy for precision medicine, and the hydrogel is expected to show huge potential in treatment of rheumatoid arthritis and has broad application prospects. Important clinical application values and market prospects are realized.

The invention discloses a polycarbonate material adjuvant and a preparation method and application thereof, and belongs to the technical field of biological medicine and immunotherapy, the polycarbonate material adjuvant comprises a biodegradable polycarbonate polymer chain segment; the STING agonist is covalently linked to a side chain of a chain segment of the polycarbonate polymer through an amido bond; based on the design thought of degradable polymer-drug coupling, the polycarbonate material adjuvant is slowly hydrolyzed under the action of in-vivo enzyme to release an STING agonist, so that continuous activation of an immune pathway is realized. According to the invention, the STING agonist is combined with the polycarbonate polymer chain segment, so that the continuous activation of the STING pathway is realized, and the cellular immune response is obviously enhanced. The polycarbonate material adjuvant can be gradually hydrolyzed and released in vivo, so that the utilization rate of the medicine in local and drainage lymph nodes is improved, meanwhile, the polycarbonate material adjuvant has good biocompatibility and safety, and a new solution is provided for immunological enhancement of rabies vaccines.

The invention generally relates to the technical field of medicines, in particular to application of a tripterine-manganese nanoparticle as a cGAS-STING pathway agonist. According to the invention, the tripterine manganese complex nanoparticle can be used as a cGAS-STNG pathway agonist by integrating the functions of a manganese complex for the first time, and the medical application of the tripterine manganese complex nanoparticle is verified. Besides, although the traditional cGAS agonist and STING agonist can enhance the immune response, the traditional cGAS agonist and STING agonist generally lack tumor specificity and controllability, may cause systemic immune response and cause unnecessary side effects; in some preferable schemes, the active oxygen response type nCel-Mn provided by the invention can realize selective immune activation of tumors and reduce side effects of the whole body.

The present invention belongs to the field of nano drug preparations, and specifically relates to a method for preparing a composite nanocarrier using inhalable liposomes and mannose-modified chitosan, and its application in the treatment of acute lung injury. The composite nanocarrier prepared by the present invention contains inhalable liposomes, which can act directly on the lungs, effectively avoid the first-pass effect of the liver, reduce systemic side effects, prolong the action time of the drug, and improve the bioavailability of the drug. Furthermore, by using mannose-modified chitosan to coat the inhalable liposomes, the composite nanocarrier can be specifically bound to the mannose receptor on the surface of macrophages, thereby achieving sustained-release targeted delivery of the drug, and surprisingly, the composite nanocarrier containing two drugs, miR-214 inhibitor and curcumin, can achieve the effect of synergistic treatment of acute lung injury under a suitable mass ratio.

The invention relates to the technical field of microneedle dressings, in particular to a diabetes wound repairing microneedle dressing and a preparation method thereof.The polyphenol medicine is nanocrystallized and wrapped in a phenylboronic acid modified polymer system, the water solubility of the polyphenol medicine can be improved, the in-vivo metabolism speed of the polyphenol medicine can be slowed down, and the bioavailability of the polyphenol medicine can be improved; the specific binding of phenylboronic acid and the hydrophilic natural high-molecular polymer can be influenced by saccharides or pH environment; in a specific physiological or pathological environment, the polyphenol drug nanoparticles can be released in a more targeted manner, the drug effect is improved, and the side effects of the whole body are reduced. Carboxymethyl chitosan is utilized to endow the microneedle dressing with antibacterial performance and polysaccharide response nanoparticles loaded with polyphenol drugs, the volume of a substrate of the microneedle dressing for repairing the wound of diabetes mellitus is shrunk at the body surface temperature, stress for the wound to shrunk inwards is applied, the area of the wound is reduced, and the wound repairing effect is improved. And polyphenol drugs are released in a diabetes mellitus high-glucose microenvironment so as to clear high-level free radicals in diabetes mellitus wounds.

This invention provides a composite hydrogel biomimetic scaffold and its preparation method. The method includes preparing a phenylboronic acid-modified chitosan and hyaluronic acid solution; preparing carboxylated polyvinyl alcohol; preparing the two into a polyvinyl alcohol-chitosan-hyaluronic acid hydrogel; adding an anti-ferroptosis drug and an anti-P2X4 receptor drug to the polyvinyl alcohol-chitosan-hyaluronic acid hydrogel to obtain a drug-loaded composite hydrogel; preparing a hybrid material with a bio-glass sheet; and fabricating the hybrid material into a biomimetic scaffold using 3D printing. Through dynamic borate ester bonds as crosslinking and responsive units, the biomimetic scaffold can achieve rapid release of the loaded drug. By adding an anti-ferroptosis drug and an anti-P2X4 receptor drug, it synergistically addresses the intertwined pathological states of oxidative stress, ferroptosis, and neuropathic pain after nerve injury through three key pathways: inhibiting lipid peroxidation, chelating free iron, and blocking purine receptor-mediated neuroinflammation.

The invention provides an interbody fusion cage which comprises an upper supporting plate, a lower supporting plate and a medicine release part, the lower supporting plate and the upper supporting plate are arranged in a spaced mode in the height direction, the lower supporting plate is located below the upper supporting plate, the medicine release part is connected between the upper supporting plate and the lower supporting plate, and the medicine release part comprises a medicine bin used for storing medicine. When the upper supporting plate and the lower supporting plate are squeezed, the medicine in the medicine bin is squeezed out. According to the interbody fusion cage disclosed by the invention, by arranging the medicine release piece comprising the medicine bin, trace and targeted medicine delivery triggered by movement is realized, local inflammation is accurately inhibited, and side effects of the whole body are greatly reduced.

The present invention discloses a two-dimensional nanothrombolytic agent and a preparation method and application thereof, wherein the two-dimensional nanothrombolytic agent is specifically composed of two-dimensional hydrogen silene nanosheets, fibrinogen and thrombolytic enzyme. The two-dimensional nanothrombolytic agent of the present invention can remain stable in the blood circulation, and after reaching the thrombus site, the fibrinogen is cut into insoluble fibrin, thereby promoting the deposition of the nanothrombolytic agent at the thrombus site, and slowly releasing the thrombolytic enzyme and hydrogen to achieve thrombolysis and anti-inflammation. The nanothrombolytic agent provided by the present invention can not only increase the in vivo circulation time and thrombus targeting of the thrombolytic enzyme, play a better thrombolytic effect and reduce the risk of bleeding, but also can achieve active oxygen scavenging and endothelial tissue repair through hydrogen treatment, regulate the thrombus microenvironment, prevent thrombus recurrence, and play a combined anti-thrombotic effect.